BTL announces EMSCULPT NEO adoption by the Dallas Cowboys
Source publication date
Site published
BTL says the team incorporated EMSCULPT NEO into its athlete-support program. The platform combines HIFEM magnetic stimulation with RF. Separately, FDA K240234 covers BTL-899MS muscle conditioning and medically supervised adjunctive limb rehabilitation. K211107 covers BTL-899 FP abdominal/thigh lipolysis and circumference reduction for skin types I–VI. These are distinct model-specific scopes.
Summary
The June announcement extends the device’s commercial presence in muscle conditioning and rehabilitation.
Editorial view
Editorial view: a useful signal of distribution beyond aesthetic clinics.
Evidence and limitations
Team adoption does not demonstrate clinical efficacy. Confirm the NEO configuration against labeling; this announcement establishes neither weight-loss efficacy nor a new FDA clearance. HIFEM differs from electrode-delivered electrical EMS.